Clinical Oncology Next Generation Sequencing (NGS) Market By Technology, Workflow and End User - Global Industry Analysis And Forecast To 2027
Published On : November 2018 Pages : 180 Category: Biotechnology Report Code : HC111674
Clinical Oncology Next Generation Sequencing (NGS) Market By Technology (Whole Genome Sequencing, Targeted Sequencing & Resequencing & Whole Exon Sequencing), Workflow (NGS Data Analysis (NGS Tertiary Data Analysis, NGS Secondary Data Analysis & NGS Primary Data Analysis), NGS Pre-Sequencing & NGS Sequencing) and End User (Hospitals & Clinics, Pharma & Biotech Entities, Clinical Research, Academic Research & Other Users) - Global Industry Analysis And Forecast To 2027
Industry Outlook
Oncology the field of medicine, that deals with diagnosis, treatment & prevention of cancer. Rate of cancer survival has increased due to major factors like improved screening tests, decreasing exposure to different danger factors by improvement in prevention techniques & development in the treatment procedures. Next Generation Sequencing (NGS) makes it quick & cost effective for sequencing of DNA & RNA, than the Sanger sequencing used earlier. Clinical Oncology Next Generation Sequencing (NGS) use is growing due to; wide number of application due to dependability over customary techniques, increasing acquisition of genetic sequence investigation, increasing initiatives by the government related to R&D of oncology, etc. Therefore, the Clinical Oncology Next Generation Sequencing (NGS) Market is anticipated to expand and has tremendous scope during the forecast period. The global Clinical Oncology Next Generation Sequencing (NGS) Market anticipated to flourish in the future by growing at a significantly higher CAGR.
Market Segmentation
The global Clinical Oncology Next Generation Sequencing (NGS) Market is based on segment, by Technology the market is segmented into Whole Genome Sequencing, Targeted Sequencing & Resequencing & Whole Exon Sequencing, by Workflow the market is segmented into NGS Data Analysis (NGS Tertiary Data Analysis, NGS Secondary Data Analysis & NGS Primary Data Analysis), NGS Pre-Sequencing & NGS Sequencing, and by End User the market is segmented into Hospitals & Clinics, Pharma & Biotech Entities, Clinical Research, Academic Research & Other Users.
- Clinical Oncology Next Generation Sequencing (NGS) Market, By Technology
- Whole Genome Sequencing
- Targeted Sequencing & Resequencing
- Whole Exon Sequencing
- Clinical Oncology Next Generation Sequencing (NGS) Market, By Workflow
- NGS Data Analysis
- NGS Tertiary Data Analysis
- NGS Secondary Data Analysis
- NGS Primary Data Analysis
- NGS Pre-Sequencing
- NGS Sequencing
- Clinical Oncology Next Generation Sequencing (NGS) Market, By End User
- Hospitals & Clinics
- Pharma & Biotech Entities
- Clinical Research
- Academic Research
- Other Users
Regional Insights
On a global front, the Clinical Oncology Next Generation Sequencing (NGS) Market covers North America (United States, Canada and Mexico), Europe (Germany, UK, France, Russia, Italy, Rest of Europe), Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific), South America (Brazil, Argentina, Columbia, Rest of South America) and Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA). North American region is leading the Clinical Oncology Next Generation Sequencing (NGS) Market due to government initiatives in this region.
Clinical Oncology Next Generation Sequencing (NGS) Market, By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Columbia
- Rest of South America
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Nigeria
- South Africa
- Rest of MEA
Competitive Analysis
The leading players in the market are Myriad Genetics, Caris Life Sciences, Illumina, Foundation Medicine, Agilent Technologies, CLC Bio, Genomatix Software, GnuBIO, GATC Biotech, Oxford Nanopore Technologies, Pacific Bioscience, Macrogen, Perkin Elmer, Life Technologies, Qiagen, DNASTAR, Exosome Diagnostics and Biomatters. The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and market share of the overall industry.
- Myriad Genetics
- Caris Life Sciences
- Illumina
- Foundation Medicine
- Agilent Technologies
- CLC Bio
- Genomatix Software
- GnuBIO
- GATC Biotech
- Oxford Nanopore Technologies
- Pacific Bioscience
- Macrogen
- Perkin Elmer
- Life Technologies
- Qiagen
- DNASTAR
- Exosome Diagnostics
- Biomatters
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2017 to 2027?
- What will be the industry market growth from 2017 to 2027?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
o Clinical Oncology Next Generation Sequencing (NGS) Market, By Technology, Estimates and Forecast, 2017-2027 ($Million)
o Whole Genome Sequencing
o Targeted Sequencing & Resequencing
o Whole Exon Sequencing
o Clinical Oncology Next Generation Sequencing (NGS) Market, By Workflow, Estimates and Forecast, 2017-2027 ($Million)
o NGS Data Analysis
§ NGS Tertiary Data Analysis
§ NGS Secondary Data Analysis
§ NGS Primary Data Analysis
o NGS Pre-Sequencing
o NGS Sequencing
o Clinical Oncology Next Generation Sequencing (NGS) Market, By End User, Estimates and Forecast, 2017-2027 ($Million)
o Hospitals & Clinics
o Pharma & Biotech Entities
o Clinical Research
o Academic Research
o Other Users
o Clinical Oncology Next Generation Sequencing (NGS) Market, By Region, Estimates and Forecast, 2017-2027 ($Million)
o North America
§ North America Clinical Oncology Next Generation Sequencing (NGS) Market, By Country
o U.S. Clinical Oncology Next Generation Sequencing (NGS) Market
o Canada Clinical Oncology Next Generation Sequencing (NGS) Market
o Mexico Clinical Oncology Next Generation Sequencing (NGS) Market
o Europe
§ Europe Clinical Oncology Next Generation Sequencing (NGS) Market, By Country
o Germany Clinical Oncology Next Generation Sequencing (NGS) Market
o UK Clinical Oncology Next Generation Sequencing (NGS) Market
o France Clinical Oncology Next Generation Sequencing (NGS) Market
o Russia Clinical Oncology Next Generation Sequencing (NGS) Market
o Italy Clinical Oncology Next Generation Sequencing (NGS) Market
o Rest of Europe Clinical Oncology Next Generation Sequencing (NGS) Market
o Asia-Pacific
§ Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market, By Country
o China Clinical Oncology Next Generation Sequencing (NGS) Market
o Japan Clinical Oncology Next Generation Sequencing (NGS) Market
o South Korea Clinical Oncology Next Generation Sequencing (NGS) Market
o India Clinical Oncology Next Generation Sequencing (NGS) Market
o Southeast Asia Clinical Oncology Next Generation Sequencing (NGS) Market
o Rest of Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market
o South America
§ South America Clinical Oncology Next Generation Sequencing (NGS) Market, By Country
o Brazil Clinical Oncology Next Generation Sequencing (NGS) Market
o Argentina Clinical Oncology Next Generation Sequencing (NGS) Market
o Columbia Clinical Oncology Next Generation Sequencing (NGS) Market
o Rest of South America Clinical Oncology Next Generation Sequencing (NGS) Market
o Middle East and Africa
§ Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Market, By Country
o Saudi Arabia Clinical Oncology Next Generation Sequencing (NGS) Market
o UAE Clinical Oncology Next Generation Sequencing (NGS) Market
o Egypt Clinical Oncology Next Generation Sequencing (NGS) Market
o Nigeria Clinical Oncology Next Generation Sequencing (NGS) Market
o South Africa Clinical Oncology Next Generation Sequencing (NGS) Market
o Rest of MEA Clinical Oncology Next Generation Sequencing (NGS) Market
Table of Contents
1. Introduction
1.1. Report Description
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
4. Market Analysis by Regions
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market Status and Outlook (2017-2027)
4.1.2. Canada Market Status and Outlook (2017-2027)
4.1.3. Mexico Market Status and Outlook (2017-2027)
4.2. Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
4.2.1. Germany Market Status and Outlook (2017-2027)
4.2.2. France Market Status and Outlook (2017-2027)
4.2.3. UK Market Status and Outlook (2017-2027)
4.2.4. Russia Market Status and Outlook (2017-2027)
4.2.5. Italy Market Status and Outlook (2017-2027)
4.2.6. Rest of Europe Market Status and Outlook (2017-2027)
4.3. Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)
4.3.1. China Market Status and Outlook (2017-2027)
4.3.2. Japan Market Status and Outlook (2017-2027)
4.3.3. Korea Market Status and Outlook (2017-2027)
4.3.4. India Market Status and Outlook (2017-2027)
4.3.5. Southeast Asia Market Status and Outlook (2017-2027)
4.3.6. Rest of Asia-Pacific Market Status and Outlook (2017-2027)
4.4. South America (Brazil, Argentina, Columbia and Rest of South America)
4.4.1. Brazil Market Status and Outlook (2017-2027)
4.4.2. Argentina Market Status and Outlook (2017-2027)
4.4.3. Columbia Market Status and Outlook (2017-2027)
4.4.4. Rest of South America Market Status and Outlook (2017-2027)
4.5. Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)
4.5.1. Saudi Arabia Market Status and Outlook (2017-2027)
4.5.2. United Arab Emirates Market Status and Outlook (2017-2027)
4.5.3. Egypt Market Status and Outlook (2017-2027)
4.5.4. Nigeria Market Status and Outlook (2017-2027)
4.5.5. South Africa Market Status and Outlook (2017-2027)
4.5.6. Turkey Market Status and Outlook (2017-2027)
4.5.7. Rest of Middle East and Africa Market Status and Outlook (2017-2027)
5. Clinical Oncology Next Generation Sequencing (NGS) Market, By Technology
5.1. Introduction
5.2. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue and Market Share by Technology (2017-2027)
5.2.1. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue and Revenue Share by Technology (2017-2027)
5.3. Whole Genome Sequencing
5.3.1. Global Whole Genome Sequencing Revenue and Growth Rate (2017-2027)
5.4. Targeted Sequencing & Resequencing
5.4.1. Global Targeted Sequencing & Resequencing Revenue and Growth Rate (2017-2027)
5.5. Whole Exon Sequencing
5.5.1. Global Whole Exon Sequencing Revenue and Growth Rate (2017-2027)
6. Clinical Oncology Next Generation Sequencing (NGS) Market, By Workflow
6.1. Introduction
6.2. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue and Market Share by Workflow (2017-2027)
6.2.1. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue and Revenue Share by Workflow (2017-2027)
6.3. NGS Data Analysis
6.3.1. Global NGS Data Analysis Revenue and Growth Rate (2017-2027)
6.3.2. Global NGS Data Analysis By Type (2017-2027)
6.3.3. NGS Tertiary Data Analysis
6.3.3.1. Global NGS Tertiary Data Analysis Revenue and Growth Rate (2017-2027)
6.3.4. NGS Secondary Data Analysis
6.3.4.1. Global NGS Secondary Data Analysis Revenue and Growth Rate (2017-2027)
6.3.5. NGS Primary Data Analysis
6.3.5.1. Global NGS Primary Data Analysis Revenue and Growth Rate (2017-2027)
6.4. NGS Pre-Sequencing
6.4.1. Global NGS Pre-Sequencing Revenue and Growth Rate (2017-2027)
6.5. NGS Sequencing
6.5.1. Global NGS Sequencing Revenue and Growth Rate (2017-2027)
7. Clinical Oncology Next Generation Sequencing (NGS) Market, By End User
7.1. Introduction
7.2. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue and Market Share by End User (2017-2027)
7.2.1. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue and Revenue Share by End User (2017-2027)
7.3. Hospitals & Clinics
7.3.1. Global Hospitals & Clinics Revenue and Growth Rate (2017-2027)
7.4. Pharma & Biotech Entities
7.4.1. Global Pharma & Biotech Entities Revenue and Growth Rate (2017-2027)
7.5. Clinical Research
7.5.1. Global Clinical Research Revenue and Growth Rate (2017-2027)
7.6. Academic Research
7.6.1. Global Academic Research Revenue and Growth Rate (2017-2027)
7.7. Other Users
7.7.1. Global Other Users Revenue and Growth Rate (2017-2027)
8. Clinical Oncology Next Generation Sequencing (NGS) Market, By Region
8.1. Introduction
8.2. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue and Market Share by Regions
8.2.1. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue by Regions (2017-2027)
8.3. North America Clinical Oncology Next Generation Sequencing (NGS) by Countries
8.3.1. North America Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2017-2027)
8.3.2. North America Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) by Countries (2017-2027)
8.3.3. United States
8.3.3.1. United States Clinical Oncology Next Generation Sequencing (NGS) Revenue (Millions USD) and Growth Rate (2017-2027)
8.3.4. Canada
8.3.4.1. Canada Clinical Oncology Next Generation Sequencing (NGS) Revenue (Millions USD) and Growth Rate (2017-2027)
8.3.5. Mexico
8.3.5.1. Mexico Clinical Oncology Next Generation Sequencing (NGS) Revenue (Millions USD) and Growth Rate (2017-2027)
8.4. Europe Clinical Oncology Next Generation Sequencing (NGS) by Countries
8.4.1. Europe Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2017-2027)
8.4.2. Europe Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) by Countries (2017-2027)
8.4.3. Germany
8.4.3.1. Germany Clinical Oncology Next Generation Sequencing (NGS) Revenue (Millions USD) and Growth Rate (2017-2027)
8.4.4. France
8.4.4.1. France Clinical Oncology Next Generation Sequencing (NGS) Revenue (Millions USD) and Growth Rate (2017-2027)
8.4.5. UK
8.4.5.1. UK Clinical Oncology Next Generation Sequencing (NGS) Revenue (Millions USD) and Growth Rate (2017-2027)
8.4.6. Russia
8.4.6.1. Russia Clinical Oncology Next Generation Sequencing (NGS) Revenue (Millions USD) and Growth Rate (2017-2027)
8.4.7. Italy
8.4.7.1. Italy Clinical Oncology Next Generation Sequencing (NGS) Revenue (Millions USD) and Growth Rate (2017-2027)
8.4.8. Rest of Europe
8.4.8.1. Rest of Europe Clinical Oncology Next Generation Sequencing (NGS) Revenue (Millions USD) and Growth Rate (2017-2027)
8.5. Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) by Countries
8.5.1. Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2017-2027)
8.5.2. Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) by Countries (2017-2027)
8.5.3. China
8.5.3.1. China Clinical Oncology Next Generation Sequencing (NGS) Revenue (Millions USD) and Growth Rate (2017-2027)
8.5.4. Japan
8.5.4.1. Japan Clinical Oncology Next Generation Sequencing (NGS) Revenue (Millions USD) and Growth Rate (2017-2027)
8.5.5. Korea
8.5.5.1. Korea Clinical Oncology Next Generation Sequencing (NGS) Revenue (Millions USD) and Growth Rate (2017-2027)
8.5.6. India
8.5.6.1. India Clinical Oncology Next Generation Sequencing (NGS) Revenue (Millions USD) and Growth Rate (2017-2027)
8.5.7. Southeast Asia
8.5.7.1. Southeast Asia Clinical Oncology Next Generation Sequencing (NGS) Revenue (Millions USD) and Growth Rate (2017-2027)
8.5.8. Rest of Asia-Pacific
8.5.8.1. Rest of Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Revenue (Millions USD) and Growth Rate (2017-2027)
8.6. South America Clinical Oncology Next Generation Sequencing (NGS) by Countries
8.6.1. South America Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2017-2027)
8.6.2. South America Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) by Countries (2017-2027)
8.6.3. Brazil
8.6.3.1. Brazil Clinical Oncology Next Generation Sequencing (NGS) Revenue (Millions USD) and Growth Rate (2017-2027)
8.6.4. Argentina
8.6.4.1. Argentina Clinical Oncology Next Generation Sequencing (NGS) Revenue (Millions USD) and Growth Rate (2017-2027)
8.6.5. Columbia
8.6.5.1. Columbia Clinical Oncology Next Generation Sequencing (NGS) Revenue (Millions USD) and Growth Rate (2017-2027)
8.6.6. Rest of South America
8.6.6.1. Rest of South America Clinical Oncology Next Generation Sequencing (NGS) Revenue (Millions USD) and Growth Rate (2017-2027)
8.7. Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) by Countries
8.7.1. Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2017-2027)
8.7.2. Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) by Countries (2017-2027)
8.7.3. Saudi Arabia
8.7.3.1. Saudi Arabia Clinical Oncology Next Generation Sequencing (NGS) Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.4. United Arab Emirates
8.7.4.1. United Arab Emirates Clinical Oncology Next Generation Sequencing (NGS) Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.5. Egypt
8.7.5.1. Egypt Clinical Oncology Next Generation Sequencing (NGS) Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.6. Nigeria
8.7.6.1. Nigeria Clinical Oncology Next Generation Sequencing (NGS) Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.7. South Africa
8.7.7.1. South Africa Clinical Oncology Next Generation Sequencing (NGS) Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.8. Turkey
8.7.8.1. Turkey Clinical Oncology Next Generation Sequencing (NGS) Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.9. Rest of Middle East and Africa
8.7.9.1. Rest of Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Revenue (Millions USD) and Growth Rate (2017-2027)
9. Company Profiles
9.1. Myriad Genetics
9.1.1. Business Overview
9.1.2. Service Portfolio
9.1.3. Strategic Developments
9.1.4. Revenue and Market Share
9.2. Caris Life Sciences
9.2.1. Business Overview
9.2.2. Service Portfolio
9.2.3. Strategic Developments
9.2.4. Revenue and Market Share
9.3. Illumina
9.3.1. Business Overview
9.3.2. Service Portfolio
9.3.3. Strategic Developments
9.3.4. Revenue and Market Share
9.4. Foundation Medicine
9.4.1. Business Overview
9.4.2. Service Portfolio
9.4.3. Strategic Developments
9.4.4. Revenue and Market Share
9.5. Agilent Technologies
9.5.1. Business Overview
9.5.2. Service Portfolio
9.5.3. Strategic Developments
9.5.4. Revenue and Market Share
9.6. CLC Bio
9.6.1. Business Overview
9.6.2. Service Portfolio
9.6.3. Strategic Developments
9.6.4. Revenue and Market Share
9.7. Genomatix Software
9.7.1. Business Overview
9.7.2. Service Portfolio
9.7.3. Strategic Developments
9.7.4. Revenue and Market Share
9.8. GnuBIO
9.8.1. Business Overview
9.8.2. Service Portfolio
9.8.3. Strategic Developments
9.8.4. Revenue and Market Share
9.9. GATC Biotech
9.9.1. Business Overview
9.9.2. Service Portfolio
9.9.3. Strategic Developments
9.9.4. Revenue and Market Share
9.10. Oxford Nanopore Technologies
9.10.1. Business Overview
9.10.2. Service Portfolio
9.10.3. Strategic Developments
9.10.4. Revenue and Market Share
9.11. Pacific Bioscience
9.11.1. Business Overview
9.11.2. Service Portfolio
9.11.3. Strategic Developments
9.11.4. Revenue and Market Share
9.12. Macrogen
9.12.1. Business Overview
9.12.2. Service Portfolio
9.12.3. Strategic Developments
9.12.4. Revenue and Market Share
9.13. Perkin Elmer
9.13.1. Business Overview
9.13.2. Service Portfolio
9.13.3. Strategic Developments
9.13.4. Revenue and Market Share
9.14. Life Technologies
9.14.1. Business Overview
9.14.2. Service Portfolio
9.14.3. Strategic Developments
9.14.4. Revenue and Market Share
9.15. Qiagen
9.15.1. Business Overview
9.15.2. Service Portfolio
9.15.3. Strategic Developments
9.15.4. Revenue and Market Share
9.16. DNASTAR
9.16.1. Business Overview
9.16.2. Service Portfolio
9.16.3. Strategic Developments
9.16.4. Revenue and Market Share
9.17. Exosome Diagnostics
9.17.1. Business Overview
9.17.2. Service Portfolio
9.17.3. Strategic Developments
9.17.4. Revenue and Market Share
9.18. Biomatters
9.18.1. Business Overview
9.18.2. Service Portfolio
9.18.3. Strategic Developments
9.18.4. Revenue and Market Share
10. Global Clinical Oncology Next Generation Sequencing (NGS) Market Competition, by Manufacturer
10.1. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue and Market Share by Manufacturer (2017-2017)
10.2. Global Clinical Oncology Next Generation Sequencing (NGS) Price By Region (2017-2017)
10.3. Top 5 Clinical Oncology Next Generation Sequencing (NGS) Manufacturer Market Share
10.4. Market Competition Trend
11. Clinical Oncology Next Generation Sequencing (NGS) Market Forecast (2017-2027)
11.1. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue (Millions USD) and Growth Rate (2017-2027)
11.2. Clinical Oncology Next Generation Sequencing (NGS) Market Forecast by Regions (2017-2027)
11.2.1. North America Clinical Oncology Next Generation Sequencing (NGS) Market Forecast (2017-2027)
11.2.1.1. United States Clinical Oncology Next Generation Sequencing (NGS) Market Forecast (2017-2027)
11.2.1.2. Canada Clinical Oncology Next Generation Sequencing (NGS) Market Forecast (2017-2027)
11.2.1.3. Mexico Clinical Oncology Next Generation Sequencing (NGS) Market Forecast (2017-2027)
11.2.2. Europe Clinical Oncology Next Generation Sequencing (NGS) Market Forecast (2017-2027)
11.2.2.1. Germany Clinical Oncology Next Generation Sequencing (NGS) Market Forecast (2017-2027)
11.2.2.2. France Clinical Oncology Next Generation Sequencing (NGS) Market Forecast (2017-2027)
11.2.2.3. UK Clinical Oncology Next Generation Sequencing (NGS) Market Forecast (2017-2027)
11.2.2.4. Russia Clinical Oncology Next Generation Sequencing (NGS) Market Forecast (2017-2027)
11.2.2.5. Italy Clinical Oncology Next Generation Sequencing (NGS) Market Forecast (2017-2027)
11.2.2.6. Rest of Europe Clinical Oncology Next Generation Sequencing (NGS) Market Forecast (2017-2027)
11.2.3. Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Forecast (2017-2027)
11.2.3.1. China Clinical Oncology Next Generation Sequencing (NGS) Market Forecast (2017-2027)
11.2.3.2. Japan Clinical Oncology Next Generation Sequencing (NGS) Market Forecast (2017-2027)
11.2.3.3. Korea Clinical Oncology Next Generation Sequencing (NGS) Market Forecast (2017-2027)
11.2.3.4. India Clinical Oncology Next Generation Sequencing (NGS) Market Forecast (2017-2027)
11.2.3.5. Southeast Asia Clinical Oncology Next Generation Sequencing (NGS) Market Forecast (2017-2027)
11.2.3.6. Rest of Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Forecast (2017-2027)
11.2.4. South America Clinical Oncology Next Generation Sequencing (NGS) Market Forecast (2017-2027)
11.2.4.1. Brazil Clinical Oncology Next Generation Sequencing (NGS) Market Forecast (2017-2027)
11.2.4.2. Argentina Clinical Oncology Next Generation Sequencing (NGS) Market Forecast (2017-2027)
11.2.4.3. Columbia Clinical Oncology Next Generation Sequencing (NGS) Market Forecast (2017-2027)
11.2.4.4. Rest of South America Clinical Oncology Next Generation Sequencing (NGS) Market Forecast (2017-2027)
11.2.5. Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Market Forecast (2017-2027)
11.2.5.1. Saudi Arabia Clinical Oncology Next Generation Sequencing (NGS) Market Forecast (2017-2027)
11.2.5.2. United Arab Emirates Clinical Oncology Next Generation Sequencing (NGS) Market Forecast (2017-2027)
11.2.5.3. Egypt Clinical Oncology Next Generation Sequencing (NGS) Market Forecast (2017-2027)
11.2.5.4. Nigeria Clinical Oncology Next Generation Sequencing (NGS) Market Forecast (2017-2027)
11.2.5.5. South Africa Clinical Oncology Next Generation Sequencing (NGS) Market Forecast (2017-2027)
11.2.5.6. Turkey Clinical Oncology Next Generation Sequencing (NGS) Market Forecast (2017-2027)
11.2.5.7. Rest of Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Market Forecast (2017-2027)
11.3. Clinical Oncology Next Generation Sequencing (NGS) Market Forecast by Technology (2017-2027)
11.3.1. Clinical Oncology Next Generation Sequencing (NGS) Forecast by Technology (2017-2027)
11.3.2. Clinical Oncology Next Generation Sequencing (NGS) Market Share Forecast by Technology (2017-2027)
11.4. Clinical Oncology Next Generation Sequencing (NGS) Market Forecast by Workflow (2017-2027)
11.4.1. Clinical Oncology Next Generation Sequencing (NGS) Forecast by Workflow (2017-2027)
11.4.2. Clinical Oncology Next Generation Sequencing (NGS) Market Share Forecast by Workflow (2017-2027)
11.5. Clinical Oncology Next Generation Sequencing (NGS) Market Forecast by End User (2017-2027)
11.5.1. Clinical Oncology Next Generation Sequencing (NGS) Forecast by End User (2017-2027)
11.5.2. Clinical Oncology Next Generation Sequencing (NGS) Market Share Forecast by End User (2017-2027)
12. List of Tables and Figures
Figure United States Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Growth Rate (2017-2027)
Figure Canada Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Growth Rate (2017-2027)
Figure Mexico Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Growth Rate (2017-2027)
Figure Germany Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Growth Rate (2017-2027)
Figure France Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Growth Rate (2017-2027)
Figure UK Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Growth Rate (2017-2027)
Figure Russia Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Growth Rate (2017-2027)
Figure Italy Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Europe Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Growth Rate (2017-2027)
Figure China Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Growth Rate (2017-2027)
Figure Japan Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Growth Rate (2017-2027)
Figure Korea Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Growth Rate (2017-2027)
Figure India Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Growth Rate (2017-2027)
Figure Southeast Asia Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Growth Rate (2017-2027)
Figure Brazil Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Growth Rate (2017-2027)
Figure Argentina Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Growth Rate (2017-2027)
Figure Columbia Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of South America Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Growth Rate (2017-2027)
Figure Saudi Arabia Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Growth Rate (2017-2027)
Figure United Arab Emirates Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Growth Rate (2017-2027)
Figure Egypt Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Growth Rate (2017-2027)
Figure Nigeria Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Growth Rate (2017-2027)
Figure South Africa Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Growth Rate (2017-2027)
Figure Turkey Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) and Growth Rate (2017-2027)
Table Global Clinical Oncology Next Generation Sequencing (NGS) Revenue and Revenue Share by Technology (2017-2027)
Figure Global Whole Genome Sequencing Revenue and Growth Rate (2017-2027)
Figure Global Targeted Sequencing & Resequencing Revenue and Growth Rate (2017-2027)
Figure Global Whole Exon Sequencing Revenue and Growth Rate (2017-2027)
Table Global Clinical Oncology Next Generation Sequencing (NGS) Revenue and Revenue Share by Workflow (2017-2027)
Figure Global NGS Data Analysis Revenue and Growth Rate (2017-2027)
Figure Global NGS Tertiary Data Analysis Revenue and Growth Rate (2017-2027)
Figure Global NGS Secondary Data Analysis Revenue and Growth Rate (2017-2027)
Figure Global NGS Primary Data Analysis Revenue and Growth Rate (2017-2027)
Figure Global NGS Pre-Sequencing Revenue and Growth Rate (2017-2027)
Figure Global NGS Sequencing Revenue and Growth Rate (2017-2027)
Table Global Clinical Oncology Next Generation Sequencing (NGS) Revenue and Revenue Share by End User (2017-2027)
Figure Global Hospitals & Clinics Revenue and Growth Rate (2017-2027)
Figure Global Pharma & Biotech Entities Revenue and Growth Rate (2017-2027)
Figure Global Clinical Research Revenue and Growth Rate (2017-2027)
Figure Global Academic Research Revenue and Growth Rate (2017-2027)
Figure Global Other Users Revenue and Growth Rate (2017-2027)
Table Global Clinical Oncology Next Generation Sequencing (NGS) Revenue by Regions (2017-2027)
Figure North America Clinical Oncology Next Generation Sequencing (NGS) Growth Rate (2017-2027)
Figure North America Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2017-2027)
Figure North America Clinical Oncology Next Generation Sequencing (NGS) by Countries (2017-2027)
Figure North America Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) by Countries (2017-2027)
Figure United States Clinical Oncology Next Generation Sequencing (NGS) Growth Rate (2017-2027)
Figure United States Clinical Oncology Next Generation Sequencing (NGS) Revenue (Millions USD) and Growth Rate (2017-2027)
Figure Canada Clinical Oncology Next Generation Sequencing (NGS) Growth Rate (2017-2027)
Figure Canada Clinical Oncology Next Generation Sequencing (NGS) Revenue (Millions USD) and Growth Rate (2017-2027)
Figure Mexico Clinical Oncology Next Generation Sequencing (NGS) Growth Rate (2017-2027)
Figure Mexico Clinical Oncology Next Generation Sequencing (NGS) Revenue (Millions USD) and Growth Rate (2017-2027)
Figure Europe Clinical Oncology Next Generation Sequencing (NGS) Growth Rate (2017-2027)
Figure Europe Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2017-2027)
Figure Europe Clinical Oncology Next Generation Sequencing (NGS) by Countries (2017-2027)
Figure Europe Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) by Countries (2017-2027)
Figure Germany Clinical Oncology Next Generation Sequencing (NGS) Growth Rate (2017-2027)
Figure Germany Clinical Oncology Next Generation Sequencing (NGS) Revenue (Millions USD) and Growth Rate (2017-2027)
Figure France Clinical Oncology Next Generation Sequencing (NGS) Growth Rate (2017-2027)
Figure France Clinical Oncology Next Generation Sequencing (NGS) Revenue (Millions USD) and Growth Rate (2017-2027)
Figure UK Clinical Oncology Next Generation Sequencing (NGS) Growth Rate (2017-2027)
Figure UK Clinical Oncology Next Generation Sequencing (NGS) Revenue (Millions USD) and Growth Rate (2017-2027)
Figure Russia Clinical Oncology Next Generation Sequencing (NGS) Growth Rate (2017-2027)
Figure Russia Clinical Oncology Next Generation Sequencing (NGS) Revenue (Millions USD) and Growth Rate (2017-2027)
Figure Italy Clinical Oncology Next Generation Sequencing (NGS) Growth Rate (2017-2027)
Figure Italy Clinical Oncology Next Generation Sequencing (NGS) Revenue (Millions USD) and Growth Rate (2017-2027)
Figure Rest of Europe Clinical Oncology Next Generation Sequencing (NGS) Growth Rate (2017-2027)
Figure Rest of Europe Clinical Oncology Next Generation Sequencing (NGS) Revenue (Millions USD) and Growth Rate (2017-2027)
Figure Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Growth Rate (2017-2027)
Figure Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2017-2027)
Figure Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) by Countries (2017-2027)
Figure Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) by Countries (2017-2027)
Figure China Clinical Oncology Next Generation Sequencing (NGS) Growth Rate (2017-2027)
Figure China Clinical Oncology Next Generation Sequencing (NGS) Revenue (Millions USD) and Growth Rate (2017-2027)
Figure Japan Clinical Oncology Next Generation Sequencing (NGS) Growth Rate (2017-2027)
Figure Japan Clinical Oncology Next Generation Sequencing (NGS) Revenue (Millions USD) and Growth Rate (2017-2027)
Figure Korea Clinical Oncology Next Generation Sequencing (NGS) Growth Rate (2017-2027)
Figure Korea Clinical Oncology Next Generation Sequencing (NGS) Revenue (Millions USD) and Growth Rate (2017-2027)
Figure India Clinical Oncology Next Generation Sequencing (NGS) Growth Rate (2017-2027)
Figure India Clinical Oncology Next Generation Sequencing (NGS) Revenue (Millions USD) and Growth Rate (2017-2027)
Figure Southeast Asia Clinical Oncology Next Generation Sequencing (NGS) Growth Rate (2017-2027)
Figure Southeast Asia Clinical Oncology Next Generation Sequencing (NGS) Revenue (Millions USD) and Growth Rate (2017-2027)
Figure Rest of Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Growth Rate (2017-2027)
Figure Rest of Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Revenue (Millions USD) and Growth Rate (2017-2027)
Figure South America Clinical Oncology Next Generation Sequencing (NGS) Growth Rate (2017-2027)
Figure South America Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2017-2027)
Figure South America Clinical Oncology Next Generation Sequencing (NGS) by Countries (2017-2027)
Figure South America Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) by Countries (2017-2027)
Figure Brazil Clinical Oncology Next Generation Sequencing (NGS) Growth Rate (2017-2027)
Figure Brazil Clinical Oncology Next Generation Sequencing (NGS) Revenue (Millions USD) and Growth Rate (2017-2027)
Figure Argentina Clinical Oncology Next Generation Sequencing (NGS) Growth Rate (2017-2027)
Figure Argentina Clinical Oncology Next Generation Sequencing (NGS) Revenue (Millions USD) and Growth Rate (2017-2027)
Figure Columbia Clinical Oncology Next Generation Sequencing (NGS) Growth Rate (2017-2027)
Figure Columbia Clinical Oncology Next Generation Sequencing (NGS) Revenue (Millions USD) and Growth Rate (2017-2027)
Figure Rest of South America Clinical Oncology Next Generation Sequencing (NGS) Growth Rate (2017-2027)
Figure Rest of South America Clinical Oncology Next Generation Sequencing (NGS) Revenue (Millions USD) and Growth Rate (2017-2027)
Figure Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Growth Rate (2017-2027)
Figure Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Revenue and Growth Rate (2017-2027)
Figure Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) by Countries (2017-2027)
Figure Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Revenue (Million USD) by Countries (2017-2027)
Figure Saudi Arabia Clinical Oncology Next Generation Sequencing (NGS) Growth Rate (2017-2027)
Figure Saudi Arabia Clinical Oncology Next Generation Sequencing (NGS) Revenue (Millions USD) and Growth Rate (2017-2027)
Figure United Arab Emirates Clinical Oncology Next Generation Sequencing (NGS) Growth Rate (2017-2027)
Figure United Arab Emirates Clinical Oncology Next Generation Sequencing (NGS) Revenue (Millions USD) and Growth Rate (2017-2027)
Figure Egypt Clinical Oncology Next Generation Sequencing (NGS) Growth Rate (2017-2027)
Figure Egypt Clinical Oncology Next Generation Sequencing (NGS) Revenue (Millions USD) and Growth Rate (2017-2027)
Figure Nigeria Clinical Oncology Next Generation Sequencing (NGS) Growth Rate (2017-2027)
Figure Nigeria Clinical Oncology Next Generation Sequencing (NGS) Revenue (Millions USD) and Growth Rate (2017-2027)
Figure South Africa Clinical Oncology Next Generation Sequencing (NGS) Growth Rate (2017-2027)
Figure South Africa Clinical Oncology Next Generation Sequencing (NGS) Revenue (Millions USD) and Growth Rate (2017-2027)
Figure Turkey Clinical Oncology Next Generation Sequencing (NGS) Growth Rate (2017-2027)
Figure Turkey Clinical Oncology Next Generation Sequencing (NGS) Revenue (Millions USD) and Growth Rate (2017-2027)
Figure Rest of Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Growth Rate (2017-2027)
Figure Rest of Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Revenue (Millions USD) and Growth Rate (2017-2027)
Table Myriad Genetics Clinical Oncology Next Generation Sequencing (NGS) Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Caris Life Sciences Clinical Oncology Next Generation Sequencing (NGS) Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Illumina Clinical Oncology Next Generation Sequencing (NGS) Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Foundation Medicine Clinical Oncology Next Generation Sequencing (NGS) Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Agilent Technologies Clinical Oncology Next Generation Sequencing (NGS) Price, Revenue, Gross Margin and Market Share (2017-2017)
Table CLC Bio Clinical Oncology Next Generation Sequencing (NGS) Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Genomatix Software Clinical Oncology Next Generation Sequencing (NGS) Price, Revenue, Gross Margin and Market Share (2017-2017)
Table GnuBIO Clinical Oncology Next Generation Sequencing (NGS) Price, Revenue, Gross Margin and Market Share (2017-2017)
Table GATC Biotech Clinical Oncology Next Generation Sequencing (NGS) Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Oxford Nanopore Technologies Clinical Oncology Next Generation Sequencing (NGS) Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Pacific Bioscience Clinical Oncology Next Generation Sequencing (NGS) Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Macrogen Clinical Oncology Next Generation Sequencing (NGS) Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Perkin Elmer Clinical Oncology Next Generation Sequencing (NGS) Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Life Technologies Clinical Oncology Next Generation Sequencing (NGS) Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Qiagen Clinical Oncology Next Generation Sequencing (NGS) Price, Revenue, Gross Margin and Market Share (2017-2017)
Table DNASTAR Clinical Oncology Next Generation Sequencing (NGS) Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Exosome Diagnostics Clinical Oncology Next Generation Sequencing (NGS) Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Biomatters Clinical Oncology Next Generation Sequencing (NGS) Price, Revenue, Gross Margin and Market Share (2017-2017)
Figure Global Clinical Oncology Next Generation Sequencing (NGS) Market Share by Manufacturer
Figure Global Clinical Oncology Next Generation Sequencing (NGS) Revenue and Market Share by Manufacturer
Table Global Clinical Oncology Next Generation Sequencing (NGS) Price by Region (2017-2017)
Figure Top 5 Clinical Oncology Next Generation Sequencing (NGS) Manufacturer (Revenue) Market Share
Figure Market Competition Trend
Figure Global Clinical Oncology Next Generation Sequencing (NGS) Revenue (Millions USD) and Growth Rate (2017-2027)
Table Clinical Oncology Next Generation Sequencing (NGS) Market Forecast by Regions (2017-2027)
Figure North America Clinical Oncology Next Generation Sequencing (NGS) Market Forecast (2017-2027)
Figure United States Clinical Oncology Next Generation Sequencing (NGS) Market Forecast (2017-2027)
Figure Canada Clinical Oncology Next Generation Sequencing (NGS) Market Forecast (2017-2027)
Figure Mexico Clinical Oncology Next Generation Sequencing (NGS) Market Forecast (2017-2027)
Figure Europe Clinical Oncology Next Generation Sequencing (NGS) Market Forecast (2017-2027)
Figure Germany Clinical Oncology Next Generation Sequencing (NGS) Market Forecast (2017-2027)
Figure France Clinical Oncology Next Generation Sequencing (NGS) Market Forecast (2017-2027)
Figure UK Clinical Oncology Next Generation Sequencing (NGS) Market Forecast (2017-2027)
Figure Russia Clinical Oncology Next Generation Sequencing (NGS) Market Forecast (2017-2027)
Figure Italy Clinical Oncology Next Generation Sequencing (NGS) Market Forecast (2017-2027)
Figure Rest of Europe Clinical Oncology Next Generation Sequencing (NGS) Market Forecast (2017-2027)
Figure Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Forecast (2017-2027)
Figure China Clinical Oncology Next Generation Sequencing (NGS) Market Forecast (2017-2027)
Figure Japan Clinical Oncology Next Generation Sequencing (NGS) Market Forecast (2017-2027)
Figure Korea Clinical Oncology Next Generation Sequencing (NGS) Market Forecast (2017-2027)
Figure India Clinical Oncology Next Generation Sequencing (NGS) Market Forecast (2017-2027)
Figure Southeast Asia Clinical Oncology Next Generation Sequencing (NGS) Market Forecast (2017-2027)
Figure Rest of Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Forecast (2017-2027)
Figure South America Clinical Oncology Next Generation Sequencing (NGS) Market Forecast (2017-2027)
Figure Brazil Clinical Oncology Next Generation Sequencing (NGS) Market Forecast (2017-2027)
Figure Argentina Clinical Oncology Next Generation Sequencing (NGS) Market Forecast (2017-2027)
Figure Columbia Clinical Oncology Next Generation Sequencing (NGS) Market Forecast (2017-2027)
Figure Rest of South America Clinical Oncology Next Generation Sequencing (NGS) Market Forecast (2017-2027)
Figure Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Market Forecast (2017-2027)
Figure Saudi Arabia Clinical Oncology Next Generation Sequencing (NGS) Market Forecast (2017-2027)
Figure United Arab Emirates Clinical Oncology Next Generation Sequencing (NGS) Market Forecast (2017-2027)
Figure Egypt Clinical Oncology Next Generation Sequencing (NGS) Market Forecast (2017-2027)
Figure Nigeria Clinical Oncology Next Generation Sequencing (NGS) Market Forecast (2017-2027)
Figure South Africa Clinical Oncology Next Generation Sequencing (NGS) Market Forecast (2017-2027)
Figure Turkey Clinical Oncology Next Generation Sequencing (NGS) Market Forecast (2017-2027)
Figure Rest of Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Market Forecast (2017-2027)
Figure Global Clinical Oncology Next Generation Sequencing (NGS) Forecast by Technology (2017-2027)
Figure Global Clinical Oncology Next Generation Sequencing (NGS) Market Share Forecast by Technology (2017-2027)
Figure Global Clinical Oncology Next Generation Sequencing (NGS) Forecast by Technology (2017-2027)
Figure Global Clinical Oncology Next Generation Sequencing (NGS) Forecast by Workflow (2017-2027)
Figure Global Clinical Oncology Next Generation Sequencing (NGS) Market Share Forecast by Workflow (2017-2027)
Figure Global Clinical Oncology Next Generation Sequencing (NGS) Forecast by Workflow (2017-2027)
Figure Global Clinical Oncology Next Generation Sequencing (NGS) Forecast by End User (2017-2027)
Figure Global Clinical Oncology Next Generation Sequencing (NGS) Market Share Forecast by End User (2017-2027)
Figure Global Clinical Oncology Next Generation Sequencing (NGS) Forecast by End User (2017-2027)
Please Note: Data related to the Companies are subject to Availability.
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|